Endo Health Solutions (ENDP) Inactive 10-Q2003 Q1 Quarterly report

Filed: 15 May 03, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: acceleration, Ackel, alternative, Amortizable, area, authoritative, back, bifurcated, bring, chargeback, clarify, contractual, covenant, customer, Dawson, debt, delivered, DepoMorphineTM, developmental, disposal, Disposed, dividend, ENDPW, entity, ER, Everidge, exit, experience, expert, extent, external, extinguishment, federal, FIN, guarantee, guarantor, guidance, indirect, interim, inventory, invoice, Landry, low, maintenance, maximum, modified, modify, motor, Nasdaq, opposed, portfolio, preclinical, prominent, Propofol, ranging, reached, recoup, recoverable, revolving, set, simultaneously, SkyePharma, source, stage, target, tentatively, transaction, trial, undiscounted, unvested, unwilling, usable, volatility, voluntary, working, yield

Removed: accretion, accrual, achieve, anticipated, arrangement, bear, Beecham, claim, compensatory, comprehensive, compulsive, conducting, consideration, deferred, depression, designated, designation, determined, discontinuation, disorder, documentation, electronic, embedded, enable, evidence, exercisability, extended, forecast, forma, fourth, furniture, GmbH, governmental, hedge, hedged, hedging, implementation, infringement, leasehold, LIBOR, marked, mg, Northstar, obsessive, OCI, panic, Paxil, Pennsylvania, planned, pro, qualify, remain, repaid, request, reversed, SmithKline, spending, system, taxable, titled, ultimate, uncertainty, utilization, valuation, void

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

ENDP similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 99.1

Certification of Chairman and Chief Executive Officer of Endo
Pursuant to 18 U.S.C. Section 1350,
as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Endo Pharmaceuticals Holdings Inc. (the “Company”) for the quarterly period ended March 31, 2003 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Carol A. Ammon, as Chairman and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

	(1)		The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)		The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/S/ CAROL A. AMMON

Name: Carol A. Ammon
Title: Chairman & Chief Executive Officer
Date: May 15, 2003

This certification accompanies the Report pursuant to § 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of §18 of the Securities Exchange Act of 1934, as amended.